Medical-Commercial Collaboration for Effective Stakeholder Engagement

STUDY OVERVIEW
BENCHMARK CLASS
SPECIAL OFFER

Non-members: Click here to review a complimentary excerpt from “Medical-Commercial Collaboration and Growth Areas: Expanding Stakeholder Engagement and Future Prospects”

STUDY OVERVIEW

The future of biopharma hinges on strategic partnerships between Medical Affairs and Commercial functions that transcend traditional boundaries, encompassing a broad spectrum of stakeholders. In an increasingly complex healthcare environment, these partnerships must evolve to address emerging challenges and leverage new opportunities.

Best Practices, LLC’s benchmarking research explores innovative strategies and effective stakeholder engagement approaches, providing Medical Affairs leaders with essential insights into new opportunity areas. The research delves into impactful collaboration approaches that extend beyond conventional methods, focusing on engaging a diverse array of external stakeholders. Additionally, it provides a forward-looking perspective on the future direction of Medical-Commercial integration, offering guidance on how to navigate and thrive in a dynamic biopharma landscape.

KEY TOPICS

Uniting Medical and Commercial to Engage Customers
Analytics Collaboration and Omnichannel Benefits
Barriers, Opportunities, and Improvement Areas
Future Collaboration Trends

KEY METRICS

Customer groups around whom Medical groups collaborate with Commercial
Digital/omnichannel benefits
Collaboration in analytics
Commercial's perspective on the value proposition of Medical Affairs
Identified opportunities for Medical Affairs to bridge Commercial gaps
Significant hurdles to effective collaboration between Medical and Commercial

SAMPLE KEY FINDINGS

Top Opportunity Areas: The greatest opportunities for Medical to address Commercial’s capability gaps mostly revolves around “Educating the Market” (76%) and “Growing Scientific Reputation” (74%).

METHODOLOGY

This study is powered by insights from 40 Medical Affairs leaders collaborating with Commercial at 33 global biopharma organizations. Functions represented in this study include: C-suite, Medical Strategy, Medical Operations, Field Medical, Medical Education, Medical Information, and Medical Excellence. Best Practices LLC also conducted deep-dive interviews with Medical Affairs leaders to capture additional insights.

Industries Profiled:
Biotech; Pharmaceutical; Biopharmaceutical; Manufacturing; Consumer Products; Diagnostic; Medical Device; Health Care; Chemical; Clinical Research; Laboratories

Companies Profiled:
Allergan; Asklepion Pharmaceuticals; LLC; AstraZeneca; Axsome Therapeutics; Bayer; bioMerieux; CSL Behring; embecta; Fresenius; Genentech; Gilead Sciences; Gr�nenthal; Jazz Pharmaceuticals; Kyowa Kirin; Merck; Merck KGaA; Merz Pharma; Micromed; Novartis; OM Pharma; Partner Therapeutics (PTx); Pfizer; Pixacore; Radius Health; Inc.; Sandoz; Sanofi; Santen; Servier; Sobi; Supernus; Takeda Pharmaceuticals; Teva Pharmaceuticals; Vertex Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.

Medical-Commercial Collaboration and Growth Areas: Expanding Stakeholder Engagement and Future Prospects

ID: 5810

Features:

Pages/Slides: 26

Published: 2024

Delivery Format: Online PDF Document

RELATED RESEARCH

1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
68559FC5D6EC0DD3000258B3B0047FCEC
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-medical-commercial-collaboration-growth-areas-expanding-stakeholder-engagement-future-prospects?opendocument
18
19opendocument
2018.97.9.171
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB